The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy

被引：3
|
作者：
Li, Qi [1 ]
Li, Li [1 ]
Wang, Yuchao [1 ]
Xu, Chunhua [1 ,4 ]
Zou, Jue [2 ,3 ]
机构：
[1] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Resp Med, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
[4] Nanjing Med Univ, Affiliated Nanjing Brain Hosp, Dept Pathol, 215 Guangzhou Rd, Nanjing 210029, Peoples R China
来源：
HELIYON | 2023年 / 9卷 / 09期
关键词：
SCLC; Chemotherapy; Prognosis; AFR; INFLAMMATION;
D O I：
10.1016/j.heliyon.2023.e19225
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
This study examined the role of pretreatment albumin-to-fibrinogen ratio (AFR) in the prognosis of small-cell lung cancer (SCLC) patients receiving first-line platinum-based chemotherapy. A total of 131 SCLC patients were enrolled. The predictive value of the AFR for progression free survival (PFS) and overall survival (OS) were evaluated by receiver operating characteristic (ROC) curve analysis. The predictive factor of survival was assessed by univariate and multivariate Cox proportional regression analysis. The correlation between OS, PFS and AFR was determined by the log-rank test using the Kaplan-Meier method. AFR was an effective predictor of OS in SCLC patients with a cut-off value of 7.78. AFR was independent risk factors for OS and PFS. Kaplan Meier analysis showed that PFS and OS in patients with high AFR levels were significantly higher than those with low AFR levels. These results suggest that AFR could be an effective predictor of survival in patients with SCLC.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] UPFRONT GENOMIC TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY
    Planchard, D.
    Lueza, B.
    Rahal, A.
    Lacroix, L.
    Ngocamus, M.
    Auger, N.
    Saulnier, P.
    Dorfmuller, P.
    Le Chevalier, T.
    Celebic, A.
    Pignon, J. P.
    Soria, J. C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 13
  • [42] The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy
    Sheng, Yi-Yun
    Zhu, Qing
    Dai, Qian-Bin
    Gao, Yu-Jie
    Bai, Yun-Xue
    Liu, Mei-Fang
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 5837 - 5848
  • [43] Performance Status and Sensitivity to First-line Chemotherapy Are Significant Prognostic Factors in Patients With Recurrent Small Cell Lung Cancer Receiving Second-line Chemotherapy
    Kim, Young Hak
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Ohmatsu, Hironobu
    Kubota, Kaoru
    Saijo, Nagahiro
    Nishiwaki, Yutaka
    CANCER, 2008, 113 (09) : 2518 - 2523
  • [44] Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
    Vassalou, Helen
    Stathopoulos, Efstathios
    Fiolitaki, Georgia
    Koutsopoulos, Anastasios
    Voutsina, Alexandra
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    LUNG CANCER, 2013, 82 (02) : 324 - 329
  • [45] Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy
    Matsubara, Taichi
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Hamatake, Motoharu
    ANTICANCER RESEARCH, 2021, 41 (10) : 5157 - 5163
  • [46] ERCC1 protein expression as a prognostic and predictive marker in patients with advanced Non-Small-Cell-Lung-Cancer (NSCLC) treated with platinum-based first-line chemotherapy
    Vassalou, H.
    Stathopoulos, E.
    Fiolitaki, G.
    Voutsina, A.
    Koutsopoulos, A.
    Trypaki, M.
    Tsakalaki, E.
    Georgoulias, V
    Mavroudis, D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S931 - S931
  • [47] Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
    Orillard, Emeline
    Adhikari, Arjab
    Malouf, Reem S.
    Calais, Francois
    Marchal, Corynne
    Westeel, Virginie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (08):
  • [48] Thromboembolic events (TE) in patients with metastatic non small cell lung cancer (NSCLC) EGFR/ALK native treated with first-line platinum-based chemotherapy
    Castellon Rubio, V. E.
    Luque Caro, R.
    Gonzalez Flores, E.
    Canosa Ruiz, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 116 - 116
  • [49] DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non-Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy
    Wang, Li-E
    Yin, Ming
    Dong, Qiong
    Stewart, David J.
    Merriman, Kelly W.
    Amos, Christopher I.
    Spitz, Margaret R.
    Wei, Qingyi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4121 - 4128
  • [50] Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
    Ma, Kewei
    Xu, Wang
    Wang, Chang
    Li, Biao
    Su, Keju
    Li, Wei
    CANCER BIOMARKERS, 2017, 18 (03) : 297 - 303
12345